Mostrar el registro sencillo del ítem

Two-part joint model for a longitudinal semicontinuous marker and a terminal event with application to metastatic colorectal cancer data

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRUSTAND, Denis
dc.contributor.authorBRIOLLAIS, Laurent
dc.contributor.authorTOURNIGAND, Christophe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRONDEAU, Virginie
dc.date.accessioned2022-03-10T12:12:37Z
dc.date.available2022-03-10T12:12:37Z
dc.date.issued2022-01
dc.identifier.issn1468-4357 (Electronic) 1465-4644 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136429
dc.description.abstractEnJoint models for a longitudinal biomarker and a terminal event have gained interests for evaluating cancer clinical trials because the tumor evolution reflects directly the state of the disease. A biomarker characterizing the tumor size evolution over time can be highly informative for assessing treatment options and could be taken into account in addition to the survival time. The biomarker often has a semicontinuous distribution, i.e., it is zero inflated and right skewed. An appropriate model is needed for the longitudinal biomarker as well as an association structure with the survival outcome. In this article, we propose a joint model for a longitudinal semicontinuous biomarker and a survival time. The semicontinuous nature of the longitudinal biomarker is specified by a two-part model, which splits its distribution into a binary outcome (first part) represented by the positive versus zero values and a continuous outcome (second part) with the positive values only. Survival times are modeled with a proportional hazards model for which we propose three association structures with the biomarker. Our simulation studies show some bias can arise in the parameter estimates when the semicontinuous nature of the biomarker is ignored, assuming the true model is a two-part model. An application to advanced metastatic colorectal cancer data from the GERCOR study is performed where our two-part model is compared to one-part joint models. Our results show that treatment arm B (FOLFOX6/FOLFIRI) is associated to higher SLD values over time and its positive association with the terminal event leads to an increased risk of death compared to treatment arm A (FOLFIRI/FOLFOX6).
dc.language.isoENen_US
dc.title.enTwo-part joint model for a longitudinal semicontinuous marker and a terminal event with application to metastatic colorectal cancer data
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/biostatistics/kxaa012en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32282877en_US
bordeaux.journalBiostatisticsen_US
bordeaux.page50-68en_US
bordeaux.volume23en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03604326
hal.version1
hal.date.transferred2022-03-10T12:12:38Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Biostatistics&rft.date=2022-01&rft.volume=23&rft.issue=1&rft.spage=50-68&rft.epage=50-68&rft.eissn=1468-4357%20(Electronic)%201465-4644%20(Linking)&rft.issn=1468-4357%20(Electronic)%201465-4644%20(Linking)&rft.au=RUSTAND,%20Denis&BRIOLLAIS,%20Laurent&TOURNIGAND,%20Christophe&RONDEAU,%20Virginie&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem